StreetInsider.com News Articles

Rhelion unit to supply psilocybin drug to Sweden university trial

Wed, 28 Oct 2026 08:03:22 -0400

Rhelion Life Sciences Corp. (CSE: RHEL, FSE: 4YX0, OTCQB: TRUFF) announced that its wholly owned subsidiary, Filament Health Corp., has signed a supply and licensing agreement with Linköping University in Sweden to provide PEX010 for a clinical trial studying psilocybin as a treatment for social anxiety disorder.

The trial, known as PsiloSAD (EU CT 2026-526267-37-00), will be led by Professor Markus Heilig at Linköping University, which is the trial sponsor. Filament Health is not the trial sponsor and is not responsible for its conduct.

PEX010 is a botanical psilocybin drug candidate manufactured using Filament's patented extraction, purification, and stabilization methods. It is

Rhelion unit to supply psilocybin drug to Sweden university trial

Wed, 28 Oct 2026 08:03:22 -0400

PEX010 is a botanical psilocybin drug candidate manufactured using Filament's patented extraction, purification, and stabilization methods. It is

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Agreement to Supply PEX010 to Linkoping University for PsiloSAD Trial in Social Anxiety Disorder

Wed, 28 Oct 2026 08:00:00 -0400

Filament has signed a supply and licensing agreement with Linköping University in Sweden for PEX010 in the PsiloSAD clinical trial in social anxiety disorder.

Toronto, Ontario--(Newsfile Corp. - October 28, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Through its wholly owned subsidiary Filament Health Corp. ("Filament"), the Company develops, manufactures and supplies PEX010, its patented, standardized, GMP manufactured botanical psilocybin drug candidate, to clinical research and compassionate access programs at leading institutions worldwide.

The Company is pleased to announce that Filament

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Agreement to Supply PEX010 to Linkoping University for PsiloSAD Trial in Social Anxiety Disorder

Wed, 28 Oct 2026 08:00:00 -0400

Filament has signed a supply and licensing agreement with Linköping University in Sweden for PEX010 in the PsiloSAD clinical trial in social anxiety disorder.

The Company is pleased to announce that Filament

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Agreement to Supply PEX010 to Linkoping University for PsiloSAD Trial in Social Anxiety Disorder

Wed, 28 Oct 2026 08:00:00 -0400

Filament has signed a supply and licensing agreement with Linköping University in Sweden for PEX010 in the PsiloSAD clinical trial in social anxiety disorder.

The Company is pleased to announce that Filament

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Agreement to Supply PEX010 to Linkoping University for PsiloSAD Trial in Social Anxiety Disorder

Wed, 28 Oct 2026 08:00:00 -0400

Filament has signed a supply and licensing agreement with Linköping University in Sweden for PEX010 in the PsiloSAD clinical trial in social anxiety disorder.

The Company is pleased to announce that Filament

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Supply Belgium's First Psilocybin Compassionate Use Program, to Help Open the Door to Patient Access for Treatment-Resistant Depressio

Fri, 16 Oct 2026 08:55:00 -0400

Filament has signed an agreement to supply PEX010 to Epsylon ASBL for what the Company believes will be the first program in Belgium to give patients access to psilocybin outside a clinical trial.
Filament will offer regulatory support and update on the program's progress towards regulatory approval.

Toronto, Ontario--(Newsfile Corp. - October 16, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Through its wholly owned subsidiary Filament Health Corp. ("Filament"), the Company develops, manufactures and supplies PEX010, its patented, standardized, GMP manufactured

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Supply Belgium's First Psilocybin Compassionate Use Program, to Help Open the Door to Patient Access for Treatment-Resistant Depressio

Fri, 16 Oct 2026 08:55:00 -0400

Filament has signed an agreement to supply PEX010 to Epsylon ASBL for what the Company believes will be the first program in Belgium to give patients access to psilocybin outside a clinical trial.
Filament will offer regulatory support and update on the program's progress towards regulatory approval.

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Supply Belgium's First Psilocybin Compassionate Use Program, to Help Open the Door to Patient Access for Treatment-Resistant Depressio

Fri, 16 Oct 2026 08:55:00 -0400

Filament has signed an agreement to supply PEX010 to Epsylon ASBL for what the Company believes will be the first program in Belgium to give patients access to psilocybin outside a clinical trial.
Filament will offer regulatory support and update on the program's progress towards regulatory approval.

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Supply Belgium's First Psilocybin Compassionate Use Program, to Help Open the Door to Patient Access for Treatment-Resistant Depressio

Fri, 16 Oct 2026 08:55:00 -0400

Filament has signed an agreement to supply PEX010 to Epsylon ASBL for what the Company believes will be the first program in Belgium to give patients access to psilocybin outside a clinical trial.
Filament will offer regulatory support and update on the program's progress towards regulatory approval.

Rhelion Life Sciences Reappoints Dr. Robin Carhart-Harris as Scientific Advisor

Wed, 14 Oct 2026 08:34:00 -0400

Dr. Robin Carhart-Harris has signed a new agreement to serve as Scientific Advisor to Rhelion Life Sciences and its wholly owned subsidiary Filament Health.

Toronto, Ontario--(Newsfile Corp. - October 14, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Through its wholly owned subsidiary Filament Health Corp. ("Filament"), the Company develops, manufactures and supplies PEX010, its patented, standardized, GMP manufactured botanical psilocybin drug candidate, to clinical research and compassionate access programs at leading institutions worldwide.

The Company is pleased to announce that

Rhelion Life Sciences Reappoints Dr. Robin Carhart-Harris as Scientific Advisor

Wed, 14 Oct 2026 08:34:00 -0400

Dr. Robin Carhart-Harris has signed a new agreement to serve as Scientific Advisor to Rhelion Life Sciences and its wholly owned subsidiary Filament Health.

The Company is pleased to announce that

Rhelion Life Sciences Reappoints Dr. Robin Carhart-Harris as Scientific Advisor

Wed, 14 Oct 2026 08:34:00 -0400

Dr. Robin Carhart-Harris has signed a new agreement to serve as Scientific Advisor to Rhelion Life Sciences and its wholly owned subsidiary Filament Health.

The Company is pleased to announce that

Rhelion Life Sciences Reappoints Dr. Robin Carhart-Harris as Scientific Advisor

Wed, 14 Oct 2026 08:34:00 -0400

Dr. Robin Carhart-Harris has signed a new agreement to serve as Scientific Advisor to Rhelion Life Sciences and its wholly owned subsidiary Filament Health.

The Company is pleased to announce that

Rhelion unit to supply psilocybin for UCSF HIV-meth study

Thu, 08 Oct 2026 08:20:18 -0400

Rhelion Life Sciences Corp. (CSE: RHEL, FSE: 4YX0, OTCQB: TRUFF) announced that its wholly owned subsidiary, Filament Health Corp., has signed a license and supply agreement with the University of California, San Francisco to provide its botanical psilocybin drug candidate, PEX010, for a Phase 2 clinical trial.

The trial, titled "PRISM: Psilocybin Recovery Intervention for Stopping Methamphetamine use" (NCT07756736), will enroll 30 participants living with HIV who have moderate to severe methamphetamine use disorder. No medication is currently approved by the U.S. Food and Drug Administration for methamphetamine use disorder.

Participants will be randomly assigned to receive a single monitored dose of

Rhelion unit to supply psilocybin for UCSF HIV-meth study

Thu, 08 Oct 2026 08:20:18 -0400

Participants will be randomly assigned to receive a single monitored dose of

Rhelion unit to supply psilocybin for UCSF HIV-meth study

Thu, 08 Oct 2026 08:20:18 -0400

Participants will be randomly assigned to receive a single monitored dose of

Rhelion unit to supply psilocybin for UCSF HIV-meth study

Thu, 08 Oct 2026 08:20:18 -0400

Participants will be randomly assigned to receive a single monitored dose of

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Licence Agreement with the University of California, San Francisco for a Phase 2 Trial of Psilocybin in Methamphetamine Use Disorde

Thu, 08 Oct 2026 08:19:00 -0400

Filament will supply PEX010 to a University of California, San Francisco trial testing whether a single dose of psilocybin can be used to help people living with HIV reduce methamphetamine use, a condition with no approved medication.

Toronto, Ontario--(Newsfile Corp. - October 8, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Through its wholly owned subsidiary Filament Health Corp. ("Filament"), the Company develops, manufactures and supplies PEX010, its patented, standardized, GMP manufactured botanical psilocybin drug candidate, to clinical research and compassionate

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Licence Agreement with the University of California, San Francisco for a Phase 2 Trial of Psilocybin in Methamphetamine Use Disorde

Thu, 08 Oct 2026 08:19:00 -0400

Filament will supply PEX010 to a University of California, San Francisco trial testing whether a single dose of psilocybin can be used to help people living with HIV reduce methamphetamine use, a condition with no approved medication.

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Licence Agreement with the University of California, San Francisco for a Phase 2 Trial of Psilocybin in Methamphetamine Use Disorde

Thu, 08 Oct 2026 08:19:00 -0400

Filament will supply PEX010 to a University of California, San Francisco trial testing whether a single dose of psilocybin can be used to help people living with HIV reduce methamphetamine use, a condition with no approved medication.

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Licence Agreement with the University of California, San Francisco for a Phase 2 Trial of Psilocybin in Methamphetamine Use Disorde

Thu, 08 Oct 2026 08:19:00 -0400

Filament will supply PEX010 to a University of California, San Francisco trial testing whether a single dose of psilocybin can be used to help people living with HIV reduce methamphetamine use, a condition with no approved medication.

Rhelion unit ships psilocybin drug to University of Calgary PTSD trial

Tue, 29 Sep 2026 07:54:13 -0400

Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) announced that its wholly owned subsidiary, Filament Health Corp., has shipped its botanical psilocybin drug candidate PEX010 to the University of Calgary for a Phase 2 clinical trial.

The trial, known as PsiPTSD (NCT06885996), is titled "Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence." It will evaluate psilocybin-assisted therapy for chronic PTSD in adult survivors of intimate partner violence. The trial is led by Dr. Chantel Debert and sponsored by the University of Calgary. Filament is a drug supplier to the trial and is not the sponsor.

PsiPTSD

Rhelion unit ships psilocybin drug to University of Calgary PTSD trial

Tue, 29 Sep 2026 07:54:13 -0400

PsiPTSD

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to the University of Calgary for Phase 2 Trial of Psilocybin-Assisted Therapy for PTSD in Survivors of Intimate Partner Viol

Tue, 29 Sep 2026 07:53:00 -0400

Filament has shipped PEX010 to the University of Calgary for PsiPTSD, a Phase 2 trial of psilocybin-assisted therapy for post-traumatic stress disorder in survivors of intimate partner violence.

Toronto, Ontario--(Newsfile Corp. - September 29, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Through its wholly owned subsidiary Filament Health Corp. ("Filament"), the Company develops, manufactures and supplies PEX010, its patented, standardized, GMP manufactured botanical psilocybin drug candidate, to clinical research and compassionate access programs at leading institutions worldwide.

The Company is pleased